Table 1 Patient and tumor characteristics
Remission after Act-D treatment (n = 96) | Resistant to Act-D treatment (n = 39) | P | |
|---|---|---|---|
Median age (years) (range) at diagnosis | 28.2 (17.9–53.7) | 30.0 (18.2–51.6) | 0.387 |
Median body weight (Kg) (range) | 57 (40–88) | 57 (44–91) | 0.804 |
Median body height (cm) (range) | 160.5 (150–170) | 160 (150–170) | 0.032 |
Median body mass index (kg/m2) (range) | 21.8 (15.6–34.4) | 21.9 (18.0–33.5) | 0.561 |
Median parity (range) | 2 (1–7) | 2 (1–6) | 0.180 |
Median gravidity (range) | 0 (0–2) | 1 (0–2) | 0.086 |
Pathology of hydatid mole | 0.425 | ||
Partial mole | 27/91 (29.7%) | 14/38 (36.8%) | |
Complete mole | 64/91 (70.3%) | 24/38 (63.2%) | |
Median numbers of curettage for hydatid mole (range) | 2 (1–2) | 2 (1–2) | 0.665 |
Invasive uterine lesions | < 0.001 | ||
No | 85 (88.5%) | 17 (43.6%) | |
Yes | 11 (11.5%) | 22 (56.4%) | |
Median diameter of invasive uterine lesions (mm) (range) | 21 (5–45) (n = 11) | 32.5 (13–87) (n = 22) | 0.026 |
FIGO staging | 0.816 | ||
Stage I | 39 (40.6%) | 15 (38.5%) | |
Stage III | 57 (59.4%) | 24 (61.5%) | |
Median FIGO/WHO scores (range) | 1 (0–6) | 3 (0–6) | < 0.001 |
Median serum β-hCG before chemotherapy (IU/L) (range) | 339 (60–46,940) | 5517 (86–159,160) | < 0.001 |